Recommendation of the President – Synacthen, Synacthen Depot (tetracosactide)

On 20 June 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 78/2025 on the validity of granting approval for reimbursement of the medicinal product Synacthen, Synacthen Depot (tetracosactide) for the following indications: drug-resistant epilepsy, drug-resistant epilepsy in the form of West syndrome, drug-resistant epilepsy in the form of Lennox-Gastaut syndrome, Kinsbourne syndrome, Landau-Kleffner syndrome

Publication in Public Information Bulletin (BIP) >>